MRNA
Moderna's First mRNA Flu Shot Clears the FDA — But Can It Actually Crack a Market Dominated by Entrenched Giants?
Shares surged +6.2% to $57.19 after the FDA approved Moderna's seasonal mRNA flu vaccine for adults 50 and older — the first influenza shot ever built on mRNA...
